[Antiplasmin drugs and factor XIII concentrates in the treatment of a patient with acute promyelocytic leukemia (M3)].
A female patient what M3 was seen to incur marked hemorrhagic diathesis during therapy. Heparin infusion was performed to inhibit disseminated intravascular coagulation (DIC). However, oozing from the puncture site of the r-subclavian vein was observed. Her data on coagulation were as follows: AT-3 greater than 100%, fibrinogen 69.0 mg, XIII less than 40%, FPA 2.9 ng/ml and FDP-D dimer 256 ng/ml. The alpha-2-plasmin inhibitor (alpha 2-PI) was 44% and FDP 160 microgram/ml. These results suggested DIC with activated fibrinolysis. Thus, epsilon aminocaproic acid in conjunction with heparin, fibrinogen, and concentrated XIII was administered. The abnormal bleeding improved with an increase of alpha 2-PI and XIII. This clinical response indicated that an activated fibrinolysis and a decreased XIII might have been responsible for provoking the bleeding of the patient.
Ryo
R
R
Blood Transfusion Service, Kobe Univ. Hospital.
Sugano
W
W
Yoshida
A
A
Adachi
M
M
Yasunaga
M
M
Yoneda
N
N
Saigo
K
K
Kondo
S
S
Yamaguchi
N
N
Nobusawa
A
A
D000328:Adult; D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000209:etiology; D004359:Drug Therapy, Combination; D005176:Factor XIII / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use; D005342:Fibrinolysis; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D000933:Antifibrinolytic Agents; D005340:Fibrinogen; D006493:Heparin; D005176:Factor XIII; D015119:Aminocaproic Acid